Seven Fleet Capital Management LP Acquires New Shares in Agios Pharmaceuticals, Inc. $AGIO

Seven Fleet Capital Management LP acquired a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 31,738 shares of the biopharmaceutical company’s stock, valued at approximately $864,000. Agios Pharmaceuticals accounts for 0.7% of Seven Fleet Capital Management LP’s portfolio, making the stock its 29th largest holding.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AGIO. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at $25,000. Invesco Ltd. raised its holdings in Agios Pharmaceuticals by 12.3% in the fourth quarter. Invesco Ltd. now owns 142,580 shares of the biopharmaceutical company’s stock valued at $3,881,000 after acquiring an additional 15,604 shares in the last quarter. XTX Topco Ltd purchased a new position in Agios Pharmaceuticals in the fourth quarter worth approximately $1,253,000. VARCOV Co. purchased a new position in Agios Pharmaceuticals in the fourth quarter worth approximately $520,000. Finally, Vestal Point Capital LP grew its holdings in Agios Pharmaceuticals by 155.9% during the 4th quarter. Vestal Point Capital LP now owns 325,000 shares of the biopharmaceutical company’s stock worth $8,846,000 after acquiring an additional 198,000 shares in the last quarter.

Agios Pharmaceuticals Trading Up 3.3%

NASDAQ:AGIO opened at $34.16 on Friday. The firm has a market cap of $2.03 billion, a P/E ratio of -4.71 and a beta of 0.59. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00. The stock’s 50 day simple moving average is $29.15 and its 200-day simple moving average is $28.61.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The business had revenue of $20.75 million for the quarter, compared to the consensus estimate of $13.30 million. The company’s revenue was up 137.7% on a year-over-year basis. Research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.28 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Sarah Gheuens sold 2,940 shares of the company’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $102,047.40. Following the transaction, the insider owned 80,277 shares of the company’s stock, valued at $2,786,414.67. This represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Cecilia Jones sold 3,141 shares of the stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $109,024.11. Following the completion of the transaction, the chief financial officer owned 54,998 shares of the company’s stock, valued at $1,908,980.58. The trade was a 5.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 12,623 shares of company stock valued at $438,144. Corporate insiders own 5.40% of the company’s stock.

Wall Street Analyst Weigh In

AGIO has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Citigroup lifted their price objective on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Bank of America lowered their target price on shares of Agios Pharmaceuticals from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, May 29th. HC Wainwright dropped their target price on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Finally, The Goldman Sachs Group raised their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Wednesday, April 1st. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $40.89.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.